Background/Aims: Kaiso (ZBTB33) expression is closely associated with the progression of many cancers and microRNA (miRNA) processing. MiR-181a plays critical roles in multiple cancers; however, its precise mechanisms in glioma have not been well clarified. The goal of this study was to evaluate the interaction between Kaiso and miR-181a in glioma. Methods: Quantitative real-time PCR (qRT-PCR) was performed to detect the levels of Kaiso and miR-181a in glioma tissues and cell lines. Cell proliferation, invasion, and the epithelial-mesenchymal transition (EMT) were evaluated to analyze the biological functions of miR-181a and Kaiso in glioma cells. The mRNA and protein levels of Kaiso were measured by qRT-PCR and western blotting, respectively. Meanwhile, luciferase assays were performed to validate Kaiso as a miR181a target in glioma cells. Results: We found that the level of miR-181a was the lowest among miR-181a-d in glioma tissues and cell lines, and the low level of miR-181a was closely associated with the increased expression of Kaiso in glioma tissues. Moreover, transfection of miR-181a significantly inhibited the proliferation, invasion, and EMT of glioma cells, whereas knockdown of miR-181a had the opposite effect. Bioinformatics analysis predicted that Kaiso was a potential target gene of miR-181a, and the luciferase reporter assay demonstrated that miR-181a could directly target Kaiso. In addition, Kaiso silencing had similar effects as miR181a overexpression in glioma cells, whereas overexpression of Kaiso in glioma cells partially reversed the inhibitory effects of the miR-181a mimic. Conclusionss: miR-181a inhibited the proliferation, invasion, and EMT of glioma cells by directly targeting and downregulating Kaiso expression.
Switzerland) and cultured in the provided astrocyte growth media supplemented with recombinant human epidermal growth factor, insulin, ascorbic acid, GA-1000, L-glutamine (GIBCO), and 5% FBS. All cells were cultured at 37°C in a humidified atmosphere of 5% on 0.1% gelatin-coated culture flasks.
Transient transfection
MiR-181a mimic, miR-181a inhibitor (2′-O-methyl-modified antisense oligonucleotides specifically targeting mature miR181a), negative control (NC), small interfering RNA (siRNA) against Kaiso (si-Kaiso), and si-NC were synthesized and purified by GenePharma (Shanghai, China). The Kaiso overexpression plasmid was generated by inserting Kaiso cDNA into the pcDNA3.1 vector, and sequencing was confirmed by GenePharma. The miR181a mimic (50 nM), miR-181a inhibitor (100 nM), si-Kaiso (100 nM), and Kaiso overexpression plasmid (100 nM) were transfected using Lipofectamine 3000 Reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's protocols. Total RNA and protein were collected 48 h after transfection.
RNA isolation and qRT-PCR
Total RNA was isolated using TRIzol according to the manufacturer's instructions, and analysis of mRNA levels was performed on the 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) with SYBR Green-Based real-time PCR for all genes. For miRNA quantification, cDNA extraction was performed using a miRNA Extraction Kit (Tiangen, Beijing, China) and TaqMan miRNA assays (Life Technologies, San Francisco, CA, USA), and reverse-transcription real-time PCR was performed for miRNA quantifications according to the manufacturer's instructions. The primer sequences used for Kaiso, proliferating cell nuclear antigen (PCNA), p21, p27, cyclin-dependent kinase 2 (CDK2), CDK4, cyclin D1, cyclin E1, matrix metalloproteinase 2 (MMP-2), MMP-9, N-cadherin, E-cadherin, vimentin, Twist, Slug, zinc finger E-box-binding homeobox 1 (ZEB1), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) detection are shown in Table 1 .
Cell proliferation assay
To study the effect of miR-181a on the proliferation of glioma cells, U251 cells were seeded in a 96-well plate and allowed to grow overnight in complete DMEM medium. Then, the medium was removed, and the cells were transfected with miR-181a mimic or inhibitor for 48 h. The Cell Proliferation ELISA-BrdU (colorimetric) Kit (Roche Diagnostics, Indianapolis, IN, USA) was used to detect cell proliferation according to the manufacturer's protocols [21] .
In vitro invasion assay
According to a previous study [22] , the Transwell invasion assay was conducted by adding 100 µL Matrigel (BD Bioscience, Franklin Lakes, NJ, USA) to the upper chamber of the Transwell and by placing cells onto the Matrigel. Next, non-invasive cells above the surface of the membrane were removed. The invasive 
Protein extraction and western blot analysis
The proteins used for western blotting were lysed with RIPA lysis buffer (Beyotime Biotechnology, Shanghai, China) containing a protease inhibitor cocktail (Roche, Basel, Switzerland). The proteins were quantified using the BCA Protein Assay Kit (Beyotime Biotechnology). The western blot system was established using the Bio-Rad Bis-Tris Gel system according to the manufacturer's instructions. Primary antibodies against Kaiso (ab124777), MMP-2 (ab37150), MMP-9 (ab76003), Twist (ab175430), Slug (ab106077; Abcam, Cambridge, UK) and ZEB1 (#3396), E-cadherin (#5296), N-cadherin (#3195), vimentin (#3390; Cell Signaling Technology Inc., Danvers, MA, USA) were prepared in 5% blocking buffer at a dilution of 1:1000. Primary antibodies were incubated with the membrane at 4°C overnight, followed by washing and incubation with secondary antibody (1:5000; Abcam, Boston, MA, USA) marked by horseradish peroxidase for 1 h at room temperature. After rinsing, the polyvinylidene difluoride membrane was transferred to the Bio-Rad ChemiDoc™ XRS system, and then 200 μL Immobilon Western Chemiluminescent HRP Substrate (Millipore, Burlington, MA, USA) was added to cover the membrane surface. The signals were captured and the intensity of the bands was quantified using Image Lab™ Software (Bio-Rad, Shanghai, China).
Measurement of MMP-2 and MMP-9 levels by enzyme-linked immunosorbent assay
According to a previous study [23] , the supernatants of U251 cells were collected after treatment, and the concentrations of MMP-2 and MMP-9 were measured using a sandwich enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer's instructions. Briefly, primary antibody was coated onto ELISA plates and incubated for 2 h at room temperature. Samples and standards were added to the wells and incubated for 1 h. Then, the wells were washed and biotinylated antibody was added for 1 h. The plates were washed again, and streptavidin conjugated to horseradish peroxidase was added for 10 min. After washing, tetramethylbenzidine was added for color development and the reaction was terminated with 1 M sulfuric acid. Absorbance was measured at 490 nm. Values were expressed as ng/mL.
Luciferase reporter assay
The 3′UTR target site was generated by PCR and luciferase reporter constructs with the Kaiso 3′UTR harboring a putative miR-181a-binding site in the pGL3 (Promega, Fitchburg, WI, USA) luciferase report vector were amplified by PCR. Cells were co-transfected with the reporter construct, control vector, and miR-181a mimic or corresponding controls using Lipofectamine 3000 (Invitrogen). After transfection for 48 h, firefly and renilla luciferase activities were measured using the dual-luciferase assay system (Promega) according to the manufacturer's instructions. All experiments were performed in triplicate.
Statistical analysis
The data are expressed as the mean ± standard error of the mean. The number of independent experiments is represented by "n". The relationship between miR-181a and clinicopathological characteristics was evaluated by the chi-square test. Correlations between miR-181a and Kaiso mRNA levels were analyzed using Pearson's correlation coefficient. Multiple comparisons were performed using one-way analysis of variance followed by Tukey's multiple-comparison test. Other comparisons were analyzed using two-tailed Student's t-test. P values less than 0.05 were considered statistically significant.
Results

High expression of Kaiso correlates with low miR-181a expression in glioma specimens
Kaiso expression is closely associated with many kinds of cancers [5] [6] [7] [8] [9] [10] [11] [12] . In this study, we detected the mRNA and protein levels of Kaiso in glioma tissues for the first time. Our results showed that the mRNA level of Kaiso was significantly increased in glioma tissues compared with that in adjacent tissues (Fig. 1A) . Furthermore, we also observed that the Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry expression of Kaiso was more enhanced in HGGs than in LGGs (Fig. 1A) . To further study Kaiso expression regulated by miRNA, we detected the levels of miR181a-d in glioma tissues, as predicted by the TargetScan 6.2 online database. We found that the levels of miR-181a-d were dramatically reduced in glioma tissues compared with adjacent tissues (Fig.  1B) , which was consistent with previous studies [16] [17] [18] [19] [20] . Furthermore, the level of miR-181a was the lowest among the four miRNAs in the miR-181 family (Fig.  1B) . Meanwhile, our results revealed that miR-181a expression was significantly downregulated in glioma tissues, especially in HGG (Fig. 1C) . To determine whether the expression of Kaiso was associated with miR-181a in glioma, Pearson's correlation analysis revealed a significant negative correlation between Kaiso and miR-181a expression in HGG (Fig. 1D) . To investigate the functional roles of Kaiso and miR-181a in glioma, several glioma cell lines were evaluated. Subsequently, we determined the levels of Kaiso and miR-181a in several glioma cell lines, namely, U87, T98, LN229, H4, U118, U251, A172, and NHAs. Compared with NHAs, the level of Kaiso in U251 cells was higher than that in other glioma cell lines (Fig. 1E) , and the level of miR-181a was lowest in U251 cells (Fig. 1F) . Therefore, U251 cells were used for subsequent experiments.
miR-181a inhibited proliferation and induced G1-phase arrest in glioma cells
After transfection with a miR181a mimic or inhibitor, qRT-PCR analysis showed that the level of miR181a was significantly upregulated or downregulated in the miR-181a mimic or miR-181 inhibitor group compared to thr NC group ( Fig. 2A) . To investigate the effect of miR-181a on glioma cell proliferation, the results from Brdu-ELISA assay indicated that introduction of miR-181a markedly inhibited the proliferation of U251 cells (Fig. 2B) . Next, flow cytometry revealed that miR181a could induce cell cycle arrest at the G0/G1 phases in U251 cells (Fig. 2C) . However, cell proliferation and the cell cycle were induced in U251 cells transfected with a miR-181a inhibitor compared with the NC group (Fig. 2B, C) . To confirm these results, we evaluated the effects of miR-181a on several proliferation-and cell cycle-related genes. As shown in Fig.  2D , the overexpression of miR-181a decreased the mRNA levels of PCNA, CDK2, CDK4, cyclin D1, and cyclin E1 and increased the mRNA levels of p21 and p27 in glioma cells. Knockdown 
of miR-181a led to the opposite effects (Fig. 2D) .
Effects of miR-181a on the invasion and EMT in glioma cells
To determine the effects of miR181a on the invasion of glioma cells, we transfected a miR-181a mimic or inhibitor into U251 cells, and the invasive ability of glioma cells was assessed by the Transwell assay. The number of invading glioma cells in the miR-181a mimic group was significantly lower than that in the NC group (Fig. 3A) . However, cell invasion ability in the miR-181a inhibitor group was stronger than that in the NC group (Fig. 3A) . Next, the expression of MMP-2 and MMP-9 was determined. Western blot analysis and ELISA assays demonstrated that MMP-2 and MMP-9 protein expression and secretion in the culture supernatants were markedly decreased by overexpression of miR-181a in U251 cells (Fig. 3B, C) , whereas knockdown of miR-181a had the reverse effect on expression (Fig. 3B, C) . Then, we examined the effect of miR-181a on the mRNA and protein expression of EMT markers in glioma cells. Overexpression of miR-181a dramatically enhanced the expression of epithelial marker E-cadherin, and reduced the expression of mesenchymal markers N-cadherin and vimentin in U251 cells 
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Cellular Physiology and Biochemistry (Fig. 4A) . Finally, we evaluated the expression of EMT-related transcription factors in U251 cells. Introduction of miR-181a significantly decreased the protein and mRNA expression of Twist, Slug, and ZEB1 in U251 cells (Fig. 4B) , whereas transfection of the miR-181a inhibitor had the opposite effects (Fig. 4A, B) . Together, our data showed that miR-181a upregulation dramatically inhibited the invasion and EMT of glioma cells.
miR-181a directly targeted the Kaiso 3′UTR
According to TargetScan 6.2, we identified a miR-181a-binding site in the 3′UTR of Kaiso (Fig. 5A) . To determine whether Kaiso is a direct target of miR-181a, luciferase plasmids containing potential Kaiso miR-181a binding sites (WT) or a mutated Kaiso 3′UTR were constructed (Fig. 5A) . Overexpression of miR-181a inhibited WT Kaiso reporter activity but not the activity of the mutated reporter construct in U251 cells, demonstrating that miR181a could specifically target the Kaiso 3′UTR by binding to the seed sequence (Fig. 5B) . Next, we confirmed the results at the mRNA and protein levels. Transfection of miR-181a significantly decreased the expression of Kaiso, whereas knockdown of miR-181a increased Kaiso expression in U251 cells (Fig. 5C ). These data indicated that miR-181a directly regulated Kaiso expression in glioma cells through 3′UTR sequence binding.
Downregulation of Kaiso by siRNA inhibited the proliferation, invasion, and EMT of glioma cells
To explore the functional roles of Kaiso in glioma cells, U251 cells were transfected with siRNA-NC or siRNA-Kaiso for 48 h, and then the proliferation, invasion, and EMT of glioma cells were evaluated. Western blot analysis showed that Kaiso expression was significantly decreased in U251 cells transfected with si-Kaiso for 48 h compared with that in the si- 
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NC group (Fig. 6A) . The Brdu-ELISA assay showed that Kaiso knockdown significantly suppressed the proliferation of glioma cells (Fig. 6B) , and the qRT-PCR assay showed that downregulation of Kaiso decreased the mRNA levels of PCNA, CDK2, CDK4, cyclin D1, and cyclin E1 and increased those of p21, p27 (Fig. 6C) . Furthermore, both the Transwell and ELISA assays suggested that decreased Kaiso expression inhibited the invasive ability of glioma cells and dramatically downregulated the expression of MMP-2 and MMP-9 ( Fig. 6D,  E) . Finally, knockdown of Kaiso resulted in inhibition of the EMT and downregulation of related transcription factors (Fig. 6F) . Consequently, Kaiso silencing had similar effects as miR-181a overexpression in glioma cells.
Overexpression of Kaiso significantly inhibited the effects of miR-181a mimic on proliferation, invasion, and EMT in glioma cells
To determine whether miR-181a targeting Kaiso was responsible for inhibition of the proliferation, invasion, and EMT of glioma cells. We constructed an expression vector that encoded the entire Kaiso coding sequence but lacked the 3′UTR. Then, we co-transfected pcDNA-Kaiso or its NC (pcDNA3.1) with the miR-181a mimic or NC into U251 cells (Fig. 7A) . The cell proliferation assay showed that concomitant overexpression of miR-181a and Kaiso abrogated the inhibitory effects of the miR-181a mimic (Fig. 7B) . Meanwhile, the mRNA levels of PCNA, CDK2, CDK4, cyclin D1, and cyclin E1 were increased and the mRNA levels of p21 and p27 were decreased in miR-181a-overexpressing glioma cells after exogenous introduction of Kaiso (Fig. 7C) . Kaiso overexpression also reversed the inhibitory effects of the miR-181a mimic on the invasion of glioma cells (Fig. 7D) and upregulated the expression of MMP-2 and MMP-9, which was inhibited by the miR-181a mimic (Fig. 7E) . Moreover, increased Kaiso expression promoted the EMT of glioma cells transfected with miR-181a mimic (Fig. 7F) . Therefore, the inhibitory effects of miR-181a were reversed by Kaiso overexpression. Taken together, these results clearly confirmed that miR-181a inhibited the proliferation, invasion, and EMT in glioma cells by targeting and downregulating Kaiso (Fig. 8) . 
Discussion
Because the involved molecular mechanisms underlying glioma remain largely unknown, the prognosis of patients with glioma is poor. Therefore, identifying the critical genes that are abnormally expressed in glioma tissues and elucidating the precise mechanisms that lead to dysregulated genes accelerating the progression of glioma are needed to develop effective glioma treatments. Several studies have reported that Kaiso expression is closely associated with many cancer types. However, some studies have considered Kaiso a pro-oncogene [8, 12, 24] , and others have suggested that it is a tumor suppressor [25] [26] [27] . In this study, both the mRNA and protein levels of Kaiso were significantly higher in glioma tissues and cells compared to those in non-cancerous tissues and normal cells. We also showed that the expression of Kaiso in HGG was significantly higher than that in LGG.
Accumulating evidence has shown that dysregulated miRNAs are closely associated with malignant biological behaviors, including proliferation, cell cycle progression, migration, invasion, EMT, apoptosis, angiogenesis, and chemoresistance [28] . Previous studies have shown that miR-181a plays both prooncogenic and tumor suppressive roles in several cancers, including cervical [29] , ovarian [30] , colorectal [31] , and hepatocellular cancers [32] , acute myeloid leukemia [33] , and gastric cancer [34] . Two recent studies demonstrated that miR-181a downregulation in glioma is closely associated with a poor prognosis [16, 20] . Accordingly, we also found that the level of miR-181a was significantly downregulated in glioma and its level was higher in HGGs than in LGGs. To determine the biological function of miR-181a in glioma, we increased or decreased the level of miR-181a in U251 cells by transfecting them with a miR-181a mimic or inhibitor, respectively. We demonstrated that 
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Cellular Physiology and Biochemistry miR-181a overexpression significantly inhibited the proliferation of glioma cells. To confirm this result, transfection of miR-181a decreased the mRNA levels of PCNA, CDK2, CDK4, cyclin D1, and cyclin E1 and increased the mRNA levels of p21 and p27 in glioma cells. Invasion is one process of metastasis. In this study, the Transwell assay showed that the overexpression or knockdown of miR-181a significantly suppressed or promoted the invasive ability of U251 cells compared with the NC group. The degradation of extracellular matrix (ECM) components by proteolytic enzymes is very important for the invasion of cancer cells [35] , and MMPs that degrade the ECM are closely associated with the invasion, metastasis, and angiogenesis of cancer cells [36] [37] [38] . In particular, both MMP-2 and MMP-9 are responsible for the invasion and EMT of malignant tumors by degrading components of the basement membrane [37, 39, 40] . We found that the expression of MMP-2 and MMP-9 was significantly decreased in U251 cells after transfection with a miR-181a mimic, whereas a miR-181a inhibitor markedly enhanced MMP-2 and MMP-9 expression. The EMT process is another key molecular step in the process of distant metastasis, as it allows cancer cells to acquire invasive properties and metastatic growth characteristics, and its activation is found in many types of malignant tumors including glioma [41, 42] . Proteins including E-cadherin, N-cadherin, vimentin, fibronectin, and β-catenin have been confirmed as the markers of EMT [43] . After transfection with a miR-181a mimic or inhibitor, we assessed the changes of the EMT markers in U251 cells. Transfection of miR-181a dramatically upregulated expression of the epithelial marker E-cadherin and downregulated expression of the mesenchymal markers vimentin and N-cadherin. Furthermore, there are many types of transcription factors, including Twist 1, Twist 2, Slug, Snail, ZEB1, and ZEB2, that are key EMT inducers [43] [44] [45] [46] . Our data indicated that upregulation of miR-181a resulted in the decreased expression of Twist1, Slug, and ZEB1. In addition, the increased expression of miR-181a inhibited the invasion and EMT of glioma cells, potentially resulting in the suppression of glioma metastasis.
Two miRNAs, namely, miR-31 and miR-181a, have been reported to inhibit cancer cells by targeting Kaiso [47, 48] . Although miR-31 was shown to inhibit Kaiso expression in prostate cancer cells [48] , no studies have demonstrated the relationship between miR-181a and Kaiso in glioma. Based on previous studies and our findings, we hypothesized that the overexpression of miR-181a would decrease the expression of Kaiso and inhibit cancerous signals such as proliferation, invasion, and EMT. Accordingly, our study showed that the overexpression of miR-181a in U251 cells enhanced the inhibition of Kaiso at both the mRNA and protein levels, and these effects were also observed with Kaiso knockdown. Restoration of Kaiso reversed the inhibitory effects of miR-181a, indicating that Kaiso may play critical roles in the progression and metastasis of glioma.
In conclusion, our results showed that miR-181a expression was significantly downregulated in glioma cells, and its level was the lowest among miR-181 family members. Overexpression of miR-181a inhibited the proliferation, invasion, and EMT of glioma cells by directly downregulating Kaiso expression. Therefore, our study provides compelling evidence supporting the roles of miR-181a and Kaiso as prognostic factors for glioma.
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